Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles. - Wikidata - awgldk - TriplyDB

Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles.

Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles.

http://www.wikidata.org/entity/Q44689542

about

Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus.Molecular virology of hepatitis E virus.Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway Hepatitis E: an overview and recent advances in vaccine research.Molecular biology and replication of hepatitis E virus.Spatial configuration of hepatitis E virus antigenic domain.Enhanced humoral response in pregnant mice immunized with liposome encapsulated recombinant neutralizing epitope protein of Hepatitis- E virus.Hepatitis E viruses in humans and animals.Hepatitis E virus outbreak in monkey facility, Japan Characterization of full genome of rat hepatitis E virus strain from Vietnam.Crystallization and preliminary X-ray diffraction analysis of recombinant hepatitis E virus-like particle.Hepatitis E vaccine.Designing, Construction and Expression of a Recombinant Fusion Protein Comprising the Hepatitis E Virus ORF2 and Rotavirus NSP4 in the Baculovirus Expression System.Insect cell technology is a versatile and robust vaccine manufacturing platform.Expression and characterization of hepatitis E virus-like particles and non-virus-like particles from insect cells.Potential Approaches to Assess the Infectivity of Hepatitis E Virus in Pork Products: A Review.World Hepatitis Day--new challenges.Vaccine Development against Zoonotic Hepatitis E Virus: Open Questions and Remaining Challenges.Development of new hepatitis E vaccines Baculovirus vector for gene delivery and vaccine development

P2860

Q27646563-3479428D-3DC0-4B24-8209-A00D216EF182 Q34045644-F15880B6-409C-4C81-9674-0D2714BD0905 Q34166393-9C43AEF7-EC38-4A72-9A8F-BA2FF9524DE5 Q34236742-6E16492A-2F89-47E1-B11E-22F3C2FD6FBC Q34334086-AB482B7A-B3AE-4B87-8949-98F99462EE86 Q34479052-FC449DA7-C6E5-4B1F-90D4-DD5CED028776 Q34485189-7E6F10FB-5EF4-433E-A8EF-606CAFA631F1 Q35683323-AE9F627E-1506-4082-AF4C-3AF5050E4FF4 Q36177327-5CE47258-F6A6-4CF5-9479-F9C7EB6A5419 Q36570554-2C045253-807B-49F7-90E1-C7362D0BF1CF Q36570902-6CC5DEDC-9170-4B5F-9547-A54E4F8051CB Q36640766-B6D57300-F745-44CA-A894-ED9C90B550B8 Q37278231-00B4D8CC-AA10-4EF2-ABC1-C3C8C347FC75 Q37589024-CAEDD407-9A89-42B1-ACAB-3FE7F01ACA2A Q37909427-C738F04F-9860-44BC-B42E-5A5C26D95E17 Q38396830-09583D77-7285-4CCB-9834-07D2DCC83D27 Q39282511-B3886D34-54F4-491A-BCC3-C24118A0266B Q42910765-C2344C7C-4707-4AEB-8855-5C114E372653 Q51784137-4217ADD6-3CA8-443C-B817-B965CC39E8D4 Q56588500-938E07F5-C4EC-4A0F-8A89-11EC68C0D651 Q57064366-58075F1A-9C10-4F97-8457-95602C0DCD91

P2860

Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles.

http://www.wikidata.org/entity/Q44689542

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Protection of cynomolgus monke ...... atitis E virus-like particles.

@en

Protection of cynomolgus monke ...... atitis E virus-like particles.

@nl

type

label

Protection of cynomolgus monke ...... atitis E virus-like particles.

@en

Protection of cynomolgus monke ...... atitis E virus-like particles.

@nl

prefLabel

Protection of cynomolgus monke ...... atitis E virus-like particles.

@en

Protection of cynomolgus monke ...... atitis E virus-like particles.

@nl

P1433

Q44689542-14B50BBA-2080-473E-A6E6-B6A4F8846888

P1476

Q44689542-FA680825-CB9F-4FB5-B859-E271E85884E6

P2093

Q44689542-08768A63-9B95-4964-8BBD-97F31F9218A0

Q44689542-1ED0AD21-62B5-48F9-A0CA-44F8F7597319

Q44689542-63FD4B04-F3AE-4CC5-B50F-93C4A9640F90

Q44689542-721FB14D-EB0F-451F-AD22-AE80CE0971CB

Q44689542-8A9334FA-D12B-4FDE-BC67-0CE544539697

Q44689542-F4CF6ABC-17E0-4F0F-8566-341D5F299154

P304

Q44689542-8A91C73C-5924-4F2D-8521-F7D165E7DBDB

P31

Q44689542-37BC0DF7-AF90-4A50-A3C7-8950AC363269

P356

Q44689542-0211626F-58D4-41DD-A500-8A1F9536933D

P407

Q44689542-A48573CC-F113-491A-9094-F9DF05B05D6D

P433

Q44689542-BC57A4A6-751F-4384-A077-951A6EFC37FF

P478

Q44689542-6C19AD6D-F21C-4F2C-9EF2-9D48D9B2E019

P577

Q44689542-37322819-AF36-4F9A-A1DC-84B49C9C38EE

P698

Q44689542-3D19466E-AC69-4DB3-BD7B-F2F9FEFDE8D1

P356

J.VACCINE.2003.08.004

P1433

P1476

Protection of cynomolgus monke ...... atitis E virus-like particles.

@en

P2093

Naokazu Takeda

http://www.w3.org/2001/XMLSchema#string

Tapankumar N Dhole

http://www.w3.org/2001/XMLSchema#string

Tatsuo Miyamura

http://www.w3.org/2001/XMLSchema#string

Tian-Cheng Li

http://www.w3.org/2001/XMLSchema#string

Yasushi Ami

http://www.w3.org/2001/XMLSchema#string

Yuriko Suzaki

http://www.w3.org/2001/XMLSchema#string

P304

370-377

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2003.08.004

http://www.w3.org/2001/XMLSchema#string

P407

P433

3-4

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14670318

http://www.w3.org/2001/XMLSchema#string